GSK1070916, also known as NMI-900 or GSK-1070916A, is an ATP-competitive inhibitor of the serine/threonine kinases Aurora B and C with potential antineoplastic activity. Aurora B/C kinase inhibitor GSK1070916A binds to and inhibits the activity of Aurora kinases B and C, which may result in inhibition of cellular division and a decrease in the proliferation of tumor cells that overexpress the Aurora kinases B and C.
Aurora Kinase Related Prodcuts:
Alisertib; Tozasertib; SP600125; Danusertib; AT9283; Hesperadin; ENMD-2076; ENMD-2076 Tartrate; MK-5108; CYC-116; CCT137690; XL228; SNS-314; SNS-314 mesylate; MK-8745